Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Fennec Pharmaceuticals Inc is a biotechnology business based in the US. Fennec Pharmaceuticals shares (FENC) are listed on the NASDAQ and all prices are listed in US Dollars. Fennec Pharmaceuticals employs 4 staff and has a market cap (total outstanding shares value) of USD$179.8 million.
|Latest market close||USD$7.72|
|52-week range||USD$4.6501 - USD$9.75|
|50-day moving average||USD$7.7999|
|200-day moving average||USD$7.4974|
|Wall St. target price||USD$15|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.669|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||5.18%|
|1 month (2020-12-18)||3.21%|
|3 months (2020-10-16)||1.31%|
|6 months (2020-07-17)||-17.34%|
|1 year (2020-01-17)||24.92%|
|2 years (2019-01-18)||10.60%|
|3 years (2018-01-18)||9.4001|
|5 years (2016-01-15)||582.64%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-45.5%|
|Return on equity TTM||-80.03%|
|Market capitalisation||USD$179.8 million|
TTM: trailing 12 months
There are currently 1.2 million Fennec Pharmaceuticals shares held short by investors – that's known as Fennec Pharmaceuticals's "short interest". This figure is 4.8% down from 1.3 million last month.
There are a few different ways that this level of interest in shorting Fennec Pharmaceuticals shares can be evaluated.
Fennec Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Fennec Pharmaceuticals shares currently shorted divided by the average quantity of Fennec Pharmaceuticals shares traded daily (recently around 127018.10526316). Fennec Pharmaceuticals's SIR currently stands at 9.5. In other words for every 100,000 Fennec Pharmaceuticals shares traded daily on the market, roughly 9500 shares are currently held short.
However Fennec Pharmaceuticals's short interest can also be evaluated against the total number of Fennec Pharmaceuticals shares, or, against the total number of tradable Fennec Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fennec Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Fennec Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0594% of the tradable shares (for every 100,000 tradable Fennec Pharmaceuticals shares, roughly 59 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Fennec Pharmaceuticals.
Find out more about how you can short Fennec Pharmaceuticals stock.
We're not expecting Fennec Pharmaceuticals to pay a dividend over the next 12 months.
Fennec Pharmaceuticals's shares were split on a 1:3 basis on 5 September 2014. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Fennec Pharmaceuticals shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Fennec Pharmaceuticals shares which in turn could have impacted Fennec Pharmaceuticals's share price.
Over the last 12 months, Fennec Pharmaceuticals's shares have ranged in value from as little as $4.6501 up to $9.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fennec Pharmaceuticals's is 0.0047. This would suggest that Fennec Pharmaceuticals's shares are less volatile than average (for this exchange).
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.